Technical analysis of ImageneBio Inc (IMA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc.
Price Performance
| 1 month | -13.20% |
| 3 months | -17.83% |
| Year-to-date | -28.55% |
| 1 year | -40.96% |
| 3 years | -90.53% |
| 5 years | -96.83% |
52-Week Range
| 52-week High | $9.10 |
| 52-week Low | $3.94 |
| Avg Volume (90d) | 17K |
Technical Indicators
| SMA 50 | $5.53 |
| SMA 200 | $5.97 |
| Beta | 0.55 |
| 30-day Volatility (annualised) | 34.9% |
| Price vs SMA 50 | -10.9% |
| Price vs SMA 200 | -17.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $8.71 | |
| 2025-11 | $6.90 | -20.8% |
| 2025-12 | $6.90 | +0.0% |
| 2026-01 | $7.51 | +8.8% |
| 2026-02 | $6.72 | -10.5% |
| 2026-03 | $5.00 | -25.6% |
| 2026-04 | $6.02 | +20.4% |
| 2026-05 | $5.88 | -2.3% |
| 2026-06 | $5.90 | +0.3% |
| 2026-07 | $5.54 | -6.1% |
| 2026-08 | $5.10 | -7.9% |
| 2026-09 | $4.93 | -3.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $4.93 |
| Market Cap | $56M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.55 |
| EV / EBITDA | 0.72 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 21.47 |